Also known as: insulinoma, pancreatic insulinoma, endogenous hyperinsulinemia, Whipple triad
Overview
Functional pancreatic neuroendocrine tumor (pNET) arising from beta cells that secretes insulin autonomously, causing fasting or postprandial hyperinsulinemic hypoglycemia. Approximately 90% are benign, solitary, and intrapancreatic; 10% are malignant and ~5-10% occur as part of MEN1.
Epidemiology
Annual incidence approximately 1-4 per 1,000,000 person-years. Median age at diagnosis 50; slight female predominance. Most are small (<2 cm) and distributed evenly across the head, body, and tail of the pancreas.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Insulinoma outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
MEN1 syndrome — insulinomas in MEN1 are more often multifocal and recur
Family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia
No identified environmental risk factors
Pathophysiology
Autonomous insulin secretion by tumor beta cells is not suppressed by hypoglycemia. C-peptide and proinsulin are co-secreted in molar amounts mirroring insulin synthesis, distinguishing endogenous hyperinsulinemia from exogenous insulin administration (in which insulin is elevated but C-peptide is suppressed). Chronic hypoglycemia leads to hypoglycemia unawareness through downregulation of counterregulatory responses.
Clinical presentation
Symptoms
Neuroglycopenic: confusion, behavioral change, blurred vision, seizures, loss of consciousness, focal neurologic deficits that may mimic stroke
Autonomic (often blunted due to hypoglycemia unawareness in chronic disease): tremor, palpitations, sweating, hunger, anxiety
Symptoms classically occur after fasting (overnight, before breakfast) or after exertion, and resolve with carbohydrate intake
Weight gain from frequent eating to prevent symptoms
Signs / physical exam
Often no exam findings between episodes
During hypoglycemia: diaphoresis, tachycardia, altered mental status, focal deficits
Look for MEN1 stigmata: multiple lipomas, angiofibromas, parathyroid or pituitary disease
Classic findings
Whipple triad: (1) symptoms consistent with hypoglycemia, (2) measured plasma glucose <55 mg/dL during symptoms, (3) relief of symptoms after glucose administration.
Differential diagnosis
Exogenous insulin administration (factitious or surreptitious) — Insulin elevated but C-peptide suppressed; consider Munchausen, access to insulin (healthcare worker, diabetic in family)
Sulfonylurea or meglitinide use (factitious or inadvertent) — Elevated insulin and C-peptide indistinguishable from insulinoma at first; sulfonylurea/meglitinide screen positive in urine or plasma
Severe liver disease or sepsis — Hepatic dysfunction or systemic illness with low insulin and C-peptide; clinical context
Postprandial (reactive) hypoglycemia — Symptoms 2-5 hours postprandially, no fasting hypoglycemia, normal 72-hour fast; consider post-bariatric surgery
Nesidioblastosis (noninsulinoma pancreatogenous hypoglycemia) — Diffuse beta-cell hyperplasia; postprandial hypoglycemia after gastric bypass; selective arterial calcium stimulation test localizes to pancreas without discrete tumor
Insulin autoimmune syndrome (Hirata disease) — High insulin levels with insulin antibodies, more common in East Asian populations or after sulfhydryl-containing drugs (methimazole)
Diagnostic workup
Diagnostic criteria
Whipple triad combined with biochemistry showing inappropriate endogenous hyperinsulinemia (elevated insulin, C-peptide, and proinsulin with suppressed beta-hydroxybutyrate) during documented hypoglycemia, after exclusion of sulfonylurea ingestion. Tumor localization completes the workup.
Labs
72-hour supervised fast — gold standard; obtain plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and sulfonylurea/meglitinide screen when glucose falls <55 mg/dL or symptoms develop
Diagnostic biochemistry during hypoglycemia: insulin ≥3 microU/mL, C-peptide ≥0.6 ng/mL, proinsulin ≥5 pmol/L, beta-hydroxybutyrate ≤2.7 mmol/L, negative sulfonylurea/meglitinide screen, appropriate glycemic response to 1 mg IV glucagon (rise ≥25 mg/dL)
Calcium, intact PTH, prolactin, IGF-1 if MEN1 suspected
Insulin antibodies if Hirata disease considered
Imaging
Contrast-enhanced (arterial-phase) CT or MRI of the pancreas — sensitivity ~70-80% for tumors ≥1 cm
Endoscopic ultrasound — particularly sensitive for small (<1 cm) intrapancreatic lesions and offers fine-needle aspiration
68Ga-DOTATATE PET/CT — useful for somatostatin-receptor-expressing tumors, particularly to evaluate for metastatic disease
Selective arterial calcium stimulation with hepatic venous sampling — reserved for biochemically confirmed insulinoma with non-localizing imaging or for differentiating insulinoma from nesidioblastosis
Intraoperative ultrasound and palpation — extremely high sensitivity when used together at experienced centers
Diagnostic algorithm
Cause of Hypoglycemia
Insulin
C-peptide
Proinsulin
Beta-hydroxybutyrate
Sulfonylurea screen
Insulinoma
High
High
High
Low
Negative
Exogenous insulin (factitious)
High
Low (suppressed)
Low
Low
Negative
Sulfonylurea/meglitinide use
High
High
High
Low
POSITIVE
Non-islet cell tumor (IGF-2)
Low
Low
Low
Low
Negative
Adrenal insufficiency / sepsis / liver
Low
Low
Low
High
Negative
Biochemistry of hypoglycemia — how to interpret the 72-hour fast.
Treatment
First-line
Surgical resection — enucleation for small, peripheral tumors; distal pancreatectomy or pancreaticoduodenectomy (Whipple) for larger, deep, or malignant lesions
Intraoperative ultrasound and palpation to confirm location and exclude additional lesions, particularly in MEN1
Frequent small meals with complex carbohydrates as a temporizing measure
Second-line / adjunct
Diazoxide — opens beta-cell K-ATP channels to inhibit insulin secretion; useful for unresectable, metastatic, or non-localized insulinoma; side effects include sodium retention, edema, and hirsutism
Somatostatin analog — octreotide, lanreotide — can paradoxically worsen hypoglycemia by suppressing counterregulatory glucagon if tumor expresses somatostatin receptor 5 disproportionately; test response carefully
Everolimus (mTOR inhibitor) — improves glycemic control in advanced metastatic insulinoma
Peptide receptor radionuclide therapy (177Lu-DOTATATE) for progressive metastatic disease with positive somatostatin receptor imaging
Hepatic artery embolization, radiofrequency ablation, or chemotherapy (streptozocin-based regimens) for hepatic metastases
Complications
Recurrent severe hypoglycemia with neuroglycopenia, seizures, motor vehicle accidents, fall injuries
Long-term neurocognitive impairment from repeated severe hypoglycemia
Hypoglycemia unawareness
Postoperative complications: pancreatic fistula, pseudocyst, diabetes mellitus (after extensive resection or in MEN1)
Metastatic disease in malignant insulinoma (~10% of cases) — most commonly to liver
PANCE pearls
Whipple triad plus inappropriate endogenous hyperinsulinemia (elevated insulin, C-peptide, AND proinsulin during hypoglycemia, with negative sulfonylurea screen) confirms insulinoma — C-peptide is the key distinguishing test against exogenous insulin administration.
Always send a sulfonylurea and meglitinide screen during the 72-hour fast — surreptitious oral hypoglycemic use perfectly mimics insulinoma biochemistry and is a tragic missed diagnosis if not excluded.
Insulinomas in MEN1 are typically multiple and recurrent — preoperative imaging strategy and surgical approach (often distal pancreatectomy with enucleation of head lesions) differ from sporadic disease.
Diazoxide can cause prominent sodium retention and edema — co-administer a thiazide diuretic to potentiate its hyperglycemic effect and counter fluid retention.
Most insulinomas are small (<2 cm) and within the pancreas, so a normal abdominal CT does not exclude the diagnosis — endoscopic ultrasound and selective arterial calcium stimulation are sensitive localizing tools.
References
Endocrine Society 2009 — Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (Cryer et al., J Clin Endocrinol Metab 2009)
NANETS 2013 — North American Neuroendocrine Tumor Society Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor: Pancreatic NETs (Kulke et al., Pancreas 2013)
ENETS 2016 — ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors (Falconi et al., Neuroendocrinology 2016)
Endocrine Society 2012 — Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (Thakker et al., J Clin Endocrinol Metab 2012)
Practice Endocrinology questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.